|
Re: Publication / Resverlogix An Author
|
3
|
Resverlogix Corp.
|
Aug 20, 2019 10:54AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 03, 2018 01:02PM
|
|
Re: Resverlogix October 2018 events
|
3
|
Resverlogix Corp.
|
Oct 18, 2018 09:17AM
|
|
Re: CKD Reata / Market Cap
|
3
|
Resverlogix Corp.
|
May 03, 2019 10:33AM
|
|
Re: Reata
|
3
|
Resverlogix Corp.
|
Apr 03, 2019 01:57PM
|
|
FGEN /CKD Readout
|
3
|
Resverlogix Corp.
|
May 10, 2019 12:05PM
|
|
Re: Abstract - first example of a "curative" effect?
|
3
|
Resverlogix Corp.
|
Oct 11, 2018 05:42AM
|
|
Re: 3 point MACE in Phase 3 should be 10% percent lower than 4 point MACE in Phase 2's
|
3
|
Resverlogix Corp.
|
Nov 06, 2018 11:26AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 06:16AM
|
|
Amarin / Mineral Oil
|
3
|
Resverlogix Corp.
|
Nov 10, 2018 03:39PM
|
|
Brd2 And Inflammation
|
3
|
Resverlogix Corp.
|
Apr 23, 2019 10:46AM
|
|
Re: BETonMACE Placebo Estimate
|
3
|
Resverlogix Corp.
|
Feb 20, 2019 09:53AM
|
|
Re: MACE event rate
|
3
|
Resverlogix Corp.
|
Nov 04, 2018 11:16AM
|
|
Re: HDL function is associated with atherosclerotic burden and cardiovascular outcomes in T2D
|
3
|
Resverlogix Corp.
|
Oct 16, 2018 05:07PM
|
|
Re: Soliciting a loan to shorters
|
3
|
Resverlogix Corp.
|
Jul 26, 2019 01:03PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex / Pitavastatin
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 08:37PM
|
|
CV Fibrosis & BRD4 i’s
|
3
|
Resverlogix Corp.
|
Aug 15, 2019 09:53AM
|
|
Re: AHA 2018
|
3
|
Resverlogix Corp.
|
Nov 11, 2018 05:03AM
|
|
Eastern
|
2
|
Resverlogix Corp.
|
Aug 13, 2019 08:36AM
|
|
Re: AHA 2018
|
2
|
Resverlogix Corp.
|
Nov 11, 2018 08:53AM
|
